Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soria

Showing results (251-260 of 6,720) with videos related to

Pageof 672
Sort By:
Thrombosis and Haemostasis|December 29, 1999
Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerizationK C Lounes, C Soria, A Valognes, et al.
British Journal of Haematology|February 5, 1998
Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogenJ Paysant, M Vasse, J Soria, et al.
Thrombosis Research|January 15, 1992
Effect of heparin and enoxaparin on platelet interaction with fibrin clotsM Mirshahi, J Soria, E Neuhart, et al.
The Journal of Clinical Investigation|April 1, 1988
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to SerJ Y Borg, M C Owen, C Soria, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 9, 2001
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysisJ P Collet, G Montalescot, C Lesty, et al.
Cellular Signalling|January 18, 2003
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cellsChristophe Denoyelle, Patricia Albanese, Georges Uzan, et al.
Thrombosis Research|August 1, 1994
Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion?M Vasse, J P Collet, J Soria, et al.
La Nouvelle Presse Medicale|December 17, 1977
[The detection of soluble fibrin complexes by a haemagglutination test. Clinical applications (author's transl)]J Soria, C Soria, S de Rodriguez, et al.
Blood|May 1, 1987
Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to HisM C Owen, J Y Borg, C Soria, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1984
Interactions of platelets with standard heparin and low molecular weight fractionsF W Dunn, C Soria, A Thomaidis, et al.
Pageof 672

Showing results (251-260 of 6,720) with videos related to

Sort By:
Pageof 672
Thrombosis and Haemostasis|December 29, 1999
Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerizationK C Lounes, C Soria, A Valognes, et al.
British Journal of Haematology|February 5, 1998
Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogenJ Paysant, M Vasse, J Soria, et al.
Thrombosis Research|January 15, 1992
Effect of heparin and enoxaparin on platelet interaction with fibrin clotsM Mirshahi, J Soria, E Neuhart, et al.
The Journal of Clinical Investigation|April 1, 1988
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to SerJ Y Borg, M C Owen, C Soria, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 9, 2001
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysisJ P Collet, G Montalescot, C Lesty, et al.
Cellular Signalling|January 18, 2003
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cellsChristophe Denoyelle, Patricia Albanese, Georges Uzan, et al.
Thrombosis Research|August 1, 1994
Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion?M Vasse, J P Collet, J Soria, et al.
La Nouvelle Presse Medicale|December 17, 1977
[The detection of soluble fibrin complexes by a haemagglutination test. Clinical applications (author's transl)]J Soria, C Soria, S de Rodriguez, et al.
Blood|May 1, 1987
Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to HisM C Owen, J Y Borg, C Soria, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1984
Interactions of platelets with standard heparin and low molecular weight fractionsF W Dunn, C Soria, A Thomaidis, et al.
Pageof 672